Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 20/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4481113 | 0.91 | CNR1 (0.50) | CNR1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL4486532 | 0.89 | CNR1 (0.51) | CNR1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL4488160 | 0.88 | CNR1 (0.54) | CNR1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL4477268 | 0.87 | CNR1 (0.51) | CNR1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL4484312 | 0.86 | CNR1 (0.55) | CNR1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL13757197 | 0.85 | CNR1 (0.45) | CNR1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL4478876 | 0.85 | CNR1 (0.50) | CNR1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL4481857 | 0.85 | CNR1 (0.64) | CNR1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL4478487 | 0.85 | CNR1 (0.52) | CNR1CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL4491826 | 0.85 | CNR1 (0.53) | CNR1CYP2C9CYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572808-B2 | Triazolopyridine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572808-B2 | Triazolopyridine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572808-B2 | Triazolopyridine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-11 | — | — | US | disclosed |
| US-20070004772-A1 | Triazolopyridine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-04 | — | — | US | disclosed |
| US-20070004772-A1 | Triazolopyridine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-04 | — | — | US | disclosed |
| US-20070004772-A1 | Triazolopyridine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004772-A1 | Triazolopyridine cannabinoid receptor 1 antagonists | CNR1, CNR2, TRPV1 | CNR1 1/4885CYP2C9 428/4885CYP2C19 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.